WebMD Health News

Study: Blood Clots More Likely from COVID Than Vaccines

coronavirus vaccine

April 16, 2021 -- The risk of developing rare but serious blood clots from COVID-19 is many times higher than from the AstraZeneca/Oxford or Pfizer and Moderna COVID-19 vaccines, researchers have concluded.

A preprint study by the University of Oxford examined the records of more than 500,000 COVID-19 patients and used that data to estimate that cerebral venous thrombosis blood clots would occurred in about 39 of every 1 million people with COVID-19.

CVT has been reported to occur in about 5 per million people after a first dose of the AstraZeneca/Oxford vaccine. In more than 480,000 people receiving either the Pfizer/BioNTech or Moderna vaccines, CVT occurred in 4 per million.

The researchers said that compared to the Pfizer or Moderna vaccines, the risk of CVT from COVID-19 was about 10 times greater.

The COVID vaccine from Johnson & Johnson, which has been put into limbo because of cases of rare blood clots in patients that received it, is an so-called adenovirus vaccine similar to AstraZeneca's but was not included in this research.

A similar pattern was seen in portal vein thrombosis (PVT) blood clots, which occurred in 436.4 per million people who had COVID. That compared to 44.9 per million for the Pfizer-Moderna vaccine group, and 1.6 per million for those receiving the AstraZeneca vaccine.

Study author Paul Harrison, professor of psychiatry at the University of Oxford, said in a press briefing that "all the evidence we have is that the risks of COVID are so much greater than whatever the risks of the vaccine might be compared to background.”

Medscape Medical News
© 2021 WebMD, LLC. All rights reserved.